文献速递毛发、甲与色素性疾病皮肤肿瘤

乳腺癌幸存者持续性化疗性脱发的临床病理特征及治疗反应

Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors.
PubMed 文献 · JAMA Dermatol · 2021-01-01

IMPORTANCE: Alopecia induced by classic chemotherapy affects up to 65% of patients and is usually reversible. However, there are increasing reports of persistent chemotherapy-induced alopecia (pCIA), especially for patients treated with taxane-containing chemotherapy regimens.…

要点

  • 含紫杉烷方案与更严重脱发相关(中位Sinclair分级4 vs 2,P<.001)。
  • 76/86例(88%)的毛发镜表现与雄激素性脱发无法区分。
  • 局部或口服米诺地尔治疗与毛发密度改善相关(中位Sinclair分级4 vs 3,P<.001)。

核心结论

  • pCIA患者多数表现为弥漫性非瘢痕性脱发或模式性脱发,含紫杉烷方案与更严重脱发相关,局部或全身治疗可使相当比例患者获得美容上显著的毛发再生。

主要发现

  • 多数患者表现为弥漫性非瘢痕性脱发(n=39)、女性型脱发(n=55)或男性型脱发(n=6),6例出现瘢痕性脱发。
  • 含紫杉烷方案用于大多数患者(92例,92%),且与更严重脱发相关(中位Sinclair分级4[IQR 3-5] vs 2[IQR 2-2.5];P<.001)。
  • 76/86例(88%)毛发镜征象与雄激素性脱发无法区分;18例活检中14例有雄激素性脱发样特征,2例瘢痕性脱发,2例兼有两者特征。
  • 局部和口服米诺地尔(有时联合抗雄激素治疗)与毛发密度改善相关(治疗前中位Sinclair分级4[IQR 3-5] vs 治疗后3[IQR 2-4];P<.001)。

关键数值与推荐

  • Sinclair分级(1-5级,1级为正常毛发密度,5级为最严重脱发阶段,头顶中央区域毛发极少或无)用于评估弥漫性脱发或中额部弥漫性毛发稀疏伴中央分缝增宽且额部发际线保留患者的严重程度。

临床怎么用

  • 对乳腺癌化疗后持续性脱发患者,应评估脱发模式并考虑毛发镜检查,含紫杉烷方案者脱发可能更重。
  • 局部或口服米诺地尔(可联合抗雄激素治疗)可用于促进毛发再生。

局限性

  • 回顾性病例系列设计,样本来自专科门诊,可能存在选择偏倚;未报告对照组的治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alopecia induced by classic chemotherapy affects up to 65% of patients and is usually reversible. However, there are increasing reports of persistent chemotherapy-induced alopecia (pCIA), especially for patients treated with taxane-containing chemotherapy regimens. OBJECTIVE: To analyze the clinicopathologic characteristics and response to treatment of patients with pCIA after chemotherapy for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: In this case series, a retrospective evaluation was performed of patients with a diagnosis of pCIA after chemotherapy for breast cancer in 4 specialist hair clinics from November 1, 2011, to February 29, 2020. MAIN OUTCOMES AND MEASURES: Clinical, trichoscopic, and histopathologic characteristics and treatment outcomes were analyzed. For patients who presented with diffuse alopecia or diffuse rarefaction of hair over the midfrontal scalp with widening of the central part line and preservation of the frontal hairline, the Sinclair scale (grades 1-5, where 1 indicates normal hair density and 5 indicates the most severe stage of hair loss, with little or no hair in the centroparietal region) was used to assess severity. RESULTS: One hundred patients (99 women [99%]; mean age at presentation, 54.0 years [range, 29.0-74.1 years]) were included. Most patients had diffuse nonscarring alopecia (n = 39), female pattern hair loss (n = 55), or male pattern hair loss (n = 6). Six patients developed cicatricial alopecia. Taxane-containing regimens were used for most patients (92 [92%]) and were associated with more severe alopecia than regimens that did not contain taxanes (median Sinclair grade, 4 [IQR, 3-5] vs 2 [IQR, 2-2.5]; P < .001). A total of 76 of 86 patients (88%) had trichoscopic signs indistinguishable from those of androgenetic alopecia. Of 18 patients who had biopsies, 14 had androgenetic alopecia-like features, 2 had cicatricial alopecia, and 2 had features of both. Both topical and oral minoxidil, sometimes combined with antiandrogen therapy, were associated with an improvement in hair density (median Sinclair grade, 4 [IQR, 3-5] before treatment vs 3 [IQR, 2-4] after treatment; P < .001). CONCLUSIONS AND RELEVANCE: This case series outlines previously unreported features of pCIA in patients with breast cancer, including a trichoscopic description. Cosmetically significant regrowth was achieved for a significant proportion of patients with topical or systemic treatments, suggesting that pCIA may be at least partly reversible.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Bhoyrul B, Asfour L, Lutz G, et al. Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors. JAMA Dermatol. 2021. PMID: 34586345. doi:10.1001/jamadermatol.2021.3676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。